TD Cowen reaffirmed a Hold rating on Tempus AI (TEM) on December 8 with an $88 price target. Analysts highlight the company's data assets as a key advantage for pharmaceutical R&D efficiency. Financials showed revenue of $334.2 million with adjusted EBITDA improving to $1.5 million. Management is shifting more volume to FDA-approved tracks and plans to submit their xT test for approval by the end of the year.